Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy
Chemotherapy-associated cardiotoxicity can present as a spectrum from arrhythmia to acute congestive heart failure. Unlike anthracyclines, proteasome inhibitors – for example, bortezomib – are not notorious for causing cardiotoxicity in absence of pre-existing cardiac dysfunction or without concomit...
Main Authors: | Marcelle G. Meseeha, Victor O. Kolade, Maximos N. Attia |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2015-12-01
|
Series: | Journal of Community Hospital Internal Medicine Perspectives |
Subjects: | |
Online Access: | http://www.jchimp.net/index.php/jchimp/article/view/28982/pdf_70 |
Similar Items
-
Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects
by: Elia Pancheri, et al.
Published: (2020-09-01) -
Update on the optimal use of bortezomib in the treatment of multiple myeloma
by: Mohan M, et al.
Published: (2017-03-01) -
Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
by: John H. Chen, et al.
Published: (2017-06-01) -
Carfilzomib induced cardiotoxicity in a multiple myeloma patient
by: Arnold Méndez-Toro, et al.
Published: (2020-09-01) -
Experimental Study on the Mechanism of Reversal of Leukemia Multidrug Resistance by Proteasome Inhibitor Bortezomib
by: Ying-chun LI, et al.
Published: (2010-08-01)